The HER2CLIMB-05 trial is a randomized, double blind, placebo-controlled, pivotal Phase 3 study evaluating the efficacy and safety of TUKYSA compared to placebo, both in combination with trastuzumab ...
Pfizer Inc. (NYSE: PFE) will present data from more than 50 company-sponsored, investigator-sponsored and collaborative research abstracts across its infectious disease pipeline and portfolio at the ...
NEW YORK-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 fourth-quarter 2026 dividend on the company’s common stock, payable December 7, 2026, ...
LITFULO significantly improved facial and total body repigmentation at Week 52 compared to placebo, with continuous improvement starting at Week 24, supporting planned regulatory filings for a ...
Study met primary endpoint, showing a statistically significant increase in the percentage of participants achieving EASI-75 versus placebo at Week 16, for the potentially first-in-class trispecific ...
Pfizer Futures is Pfizer’s paid summer internship program for undergraduate students who want hands on experience at a global biopharmaceutical company. As a Pfizer Futures intern, you’ll work on real ...
Long before reaching pharmacy shelves, every new medicine must complete one or more clinical trials. But before researchers can determine whether a potential new treatment is effective, they have to ...
At Pfizer, we’re eager to connect with you. Follow Pfizer and our CEO Albert Bourla’s Influencer posts on LinkedIn and Twitter. Get your Pfizer news in small bits by following @Pfizer and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results